Advertisement
Mayo Clinic Proceedings Home
MCP Digital Health Home
Medical image| Volume 96, ISSUE 11, P2746-2747, November 2021

Papillary Urothelial Carcinoma

      A 70-year-old man with a history of hypertension and asymptomatic atrial flutter presented with pyuria on urine microscopic examination. Cystoscopy revealed bladder lesions emanating from the left ureteral orifice and posterior lateral wall (Figure, A and B). Upper tract evaluation with ureteropyelograms revealed no other lesions. Transurethral resection of the bladder tumors was performed to further characterize these lesions. Histopathological examination revealed the presence of noninvasive high-grade urothelial carcinoma (Figure, C and D). Specifically, these grossly exophytic lesions correspond to papillary structures with well-defined fibrovascular cores that are lined by urothelial cells with loss of cell polarity and marked cytologic atypia.
      Figure thumbnail gr1
      FigureCystoscopy revealed bladder lesions emanating from the left ureteral orifice and posterior lateral wall (A and B). Histopathological examination revealed the presence of noninvasive high-grade urothelial carcinoma (C and D).
      Tumor grade, presence of tumor invasion, tumor size, recurrence, and multifocality are some factors that predict the risk of disease progression.
      • Babjuk M.
      • Böhle A.
      • Burger M.
      • et al.
      EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016.
      In this patient, the presence of high-grade lesion would stratify him as having a high risk of progression.
      • Soukup V.
      • Čapoun O.
      • Cohen D.
      • et al.
      Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
      Patients with high-risk disease are typically managed with transurethral resection of the bladder tumor coupled with intravesical therapy.
      • Babjuk M.
      • Böhle A.
      • Burger M.
      • et al.
      EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016.
      ,
      • Hall M.C.
      • Chang S.S.
      • Dalbagni G.
      • et al.
      Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
      This is typically followed by surveillance to monitor for disease recurrence or progression.

      References

        • Babjuk M.
        • Böhle A.
        • Burger M.
        • et al.
        EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016.
        Eur Urol. 2017; 71: 447-461
        • Soukup V.
        • Čapoun O.
        • Cohen D.
        • et al.
        Prognostic performance and reproducibility of the 1973 and 2004/2016 World Health Organization grading classification systems in non-muscle-invasive bladder cancer: a European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review.
        Eur Urol. 2017; 72: 801-813
        • Hall M.C.
        • Chang S.S.
        • Dalbagni G.
        • et al.
        Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update.
        J Urol. 2007; 178: 2314-2330